MétaCan
Menu
Back to cohort
Record W4410014449 · doi:10.1016/j.euo.2025.03.001

Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials

2025· article· en· W4410014449 on OpenAlexaff
Christopher J.D. Wallis, Sara Ekberg, Alicia K. Morgans, Martin Boegemann, Noman Paracha, Michael J. Crowther, Neal D. Shore

Bibliographic record

VenueEuropean Urology Oncology · 2025
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsMount Sinai Hospital
FundersPharmaceuticals Bayer
KeywordsMedicineProstate cancerOncologyProstate-specific antigenInternal medicineProstateCancerClinical trialHormone

Abstract

fetched live from OpenAlex

BACKGROUND AND OBJECTIVE: Prostate-specific antigen (PSA) is a critical biomarker in metastatic hormone-sensitive prostate cancer (mHSPC), offering insights into disease progression and treatment efficacy. An early PSA response to intensified therapy has significant prognostic implications; however, traditional methods often categorize PSA levels and focus on fixed time points, neglecting its dynamic nature. Joint models integrate longitudinal PSA trajectories and survival outcomes to provide a more comprehensive analysis. This study aims to evaluate the association between longitudinal PSA trajectories and overall survival (OS) in patients with mHSPC. METHODS: We analyzed data from two phase 3 trials: ARASENS (n = 1305; androgen deprivation therapy [ADT] + docetaxel ± darolutamide) and ARANOTE (n = 669; ADT ± darolutamide). PSA trajectories were modeled using linear mixed models with restricted cubic splines, while OS was assessed using a Weibull model. Longitudinal PSA changes and OS were linked through joint modeling. KEY FINDINGS AND LIMITATIONS: In ARASENS, each doubling of the PSA decline rate was associated with a reduction in mortality rate of 29% (hazard ratio [HR] 0.71, 95% confidence interval [CI]: 0.69, 0.74); in ARANOTE, the reduction was 25% (HR 0.75, 95% CI: 0.72, 0.78). Higher baseline PSA levels and sharper postnadir increases were linked to worse outcomes. Darolutamide-treated patients showed favorable PSA trajectories, marked by steeper declines, prolonged nadirs, and slower increases, translating into improved OS. Limitations include interim OS data in ARANOTE and influence of prior treatments on baseline PSA. CONCLUSIONS AND CLINICAL IMPLICATIONS: Joint modeling demonstrates a strong association between PSA dynamics and OS, underscoring darolutamide's potential to positively influence PSA trajectories and improve survival in mHSPC.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.153
Threshold uncertainty score0.598

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.031
GPT teacher head0.336
Teacher spread0.305 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Urology OncologySame topicProstate Cancer Treatment and ResearchFrench-language works237,207